Opterion Health is focused to bring innovation to dialysis care and foster home dialysis to improve the quality of life for patients, their caregivers and loved ones as well as attempt to increase the survival rates of people who suffer from chronic kidney disease.
The Board and the Management Team of Opterion Health AG thanks🙏 Stefan Wohlfeil for his support and his outstanding contribution to the continuing success of the company. Stefan Wohlfeil has decided to retire and step down as a member of the Board of Directors, but remains a partner and shareholder. At the Opterion Health AG extraordinary General Meeting, held on September 19, 2023, the shareholders elected Jan-Anders Karlsson and Robert Leitz as new members of
Muttenz, Switzerland, 20 September 2023 – Opterion Health AG, a Swiss-based life sciences company developing the first major innovation in peritoneal dialysis (PD) for two decades, today announced the successful completion of a CHF 6.5m financing round. The proceeds will be used to complete ongoing preclinical activities and prepare for the start of Phase I studies. Separately, Stefan Wohlfeil has decided to retire and step down as a member of the Board of Directors. At the Extraordinary General Meeting (EGM) on 19 September 2023, shareholders elected Jan-Anders Karlsson and Robert Leitz as new members of the Board of Directors.
At this year’s Annual General Meeting, the Opterion Health shareholders voted in favour of all proposed topics. Also the members of the Board of Directors were re-elected – congratulations to David Ebsworth, Ricardo Cordero and Stefan Wohlfeil. The business and scientific updates presented by the CEO Peter Reinemer and Guido Grentzmann (Founder & CSO) highlighted that the company is well on track with the development of OPT 100, Opterion Health’s lead development product – a
Opterion Health engaged Ulrike Grimm in June 2020 to establish project excellence for its development program.
Ulrike started her career as a sales representative for Sanol Pharma and joined Merck KGaA in 1997, where she held roles of increasing responsibility starting as team leader for R&D projects and continuing as product leader for Merck’s second commercial oncology drug.
From 2007 to 2010 she was the Vice President of Project and Portfolio Management at Fresenius Biotech. Ulrike joined Vifor Pharma in 2010 and served as the Vice President for Project and Alliance Management as well as Clinical Operations during the next eight years. In 2019 Ulrike started her own consulting company Pro2S AG.
Peter Reinemer, PhD, MBA, has been appointed as Chief Executive Officer (CEO) of the company as of February 2023. He joined Opterion in July 2021 as Chief Technology Officer (CTO) and will assume this position in addition to his new role for the time being.
Peter has more than 30 years of experience in the pharmaceutical and biotechnology industries, and began his career at Bayer Pharma, where he spent over 10 years in discovery research in Germany and Japan. He subsequently served as Chief Scientific Officer, Head of Business Development, Chief Operating Officer and Senior Vice President, Corporate Development, of Proteros, a discovery services company based in Munich and Boston. He co-founded IMD Natural Solutions, developer of the all-natural preservative agent Nagardo®, which was acquired by Lanxess AG in 2017. Peter holds a Master in Chemistry, a PhD from the Max Planck Institute for Biochemistry/TU Munich (Structural Biology, Prof. Dr. Robert Huber), and an MBA.
Mylène Fleurant joined Opterion Health in July 2021 as Head of Quality having spent more than 20 years in leading quality (QA) functions in the life sciences industry. She worked for 10 years as Region Head Quality Europe at Novartis and implemented global quality systems at Merck Serono. Prior to founding her own consulting company in 2019, Mylène was Global Head of QA at Novimmune and VP Quality Affairs at Alvotech.
Mylène is a chemical engineer and holds a master’s degree from the University of Sherbrooke, Canada, as well as a degree in Quality Assurance Management from L’Ecole de Technologie Supérieure (ETS) at the University of Quebec.
Daniel Lustenberger is an experienced international finance, accounting and management consulting professional and joined Opterion Health in September 2021 as Chief Financial Officer (CFO). He is a Swiss Certified Public Accountant, holds an Executive MBA from IMD in Lausanne and has 20 years of life sciences and technology experience.
Daniel supports several start-ups and growth companies, particularly in the life sciences and high tech sectors, as a part-time CFO, business advisor and board member.
Prior to Opterion, he held senior finance positions with Vifor Pharma, Gategroup and DKSH. In his early career, he spent several years with PwC, providing advisory services in M&A, IPOs, process and system improvements, corporate governance and risk management.
Andreas Schmid has more than 25 years of experience in Finance in the Life Sciences. He worked as a Pharma Analyst at Merrill Lynch and also has experience in fund raising as well as business development.
During the span of his career Andreas was one of the highest-ranked dialysis and generic pharma analysts, with special expertise in European and CEE/emerging markets. His coverage universe included companies such as Fresenius/FMC (Germany), Gambro (Sweden), Stada (Germany) and Aspen (South Africa). Furthermore, he played a major part in the IPOs of Zentiva (Czech Republic) and Hikma (Jordan). Andreas has also been active as a speaker at various industry conferences, for example in New York, Frankfurt, but also in Warsaw and other Eastern European countries.
In addition, Andreas works as finance lecturer at the Hochschule Pforzheim and is a board member of the German shareholder association SdK.
